BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
The plant cell culture biotechnology company said revenue for the first quarter of 2026 rose 8% year over year to $8.5 million, compared with $7.9 million in the prior-year period. Gross profit increased to $5 million, or 59% of revenue, from $4.6 million, or 58% of revenue, a year earlier.
